Market Overview:
The global depressive disorder market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of depressive disorders, growing awareness about depression and its treatment, and rising demand for antidepressants. Based on type, the global depressive disorder market is segmented into tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), serotonin antagonist and reuptake inhibitors (SARIs), and others. The SSRI segment is expected to grow at a higher CAGR during the forecast period owing to their high efficacy and safety profile. Based on application, the global depressive disorder market is segmented into hospitals, ambulatory surgical centers, diagnostic centers, homecare settings, long term care centers, and others. The hospitals segment accounted for the largest share of the global antidepressant drugs market in 2017 owing to increased access to healthcare facilities coupled with rising incidence of depression across all age groups. Geographically speaking North America held majority share in 2017 followed by Europe while Asia Pacific region has emerged as fastest growing region over last few years due To this factors Asia Pacific region projected register highest CAGR over forecast period .Some key players operating in this field are Pfizer Inc., Eli Lilly & Co., GlaxoSmithKline plc.
Product Definition:
Depressive disorder is a mental health condition that causes persistent feelings of sadness and loss of interest in activities. It affects how you think, feel, and behave and can lead to a variety of emotional and physical problems.
Tricyclic Antidepressants:
Tricyclic antidepressants (TCAs) are the most commonly prescribed type of medication for depression. They are also used in cases where patients have not responded to other treatments such as ECT and shock therapy. TCA is a class of drugs that includes amitriptyline, imipramine, doxepin, and others.
Selective Serotonin Reuptake Inhibitors:
SSRI's are used to treat depression by decreasing the amount of serotonin in the brain. SSRIs block a certain pathway that allows tryptophan, a chemical found in the body, to enter brain cells; this inhibition leads to low levels of serotonin.
The Selective Serotonin Reuptake Inhibitors (SSRI) market is expected to grow at an approximate CAGR of XX% over the forecast period owing to increasing prevalence.
Application Insights:
The market is segmented by application into hospitals, ambulatory surgical centers, diagnostic centers, homecare settings and long-term care centers. The homecare settings segment held the largest share in 2017 owing to increasing awareness about depression among a wider population. Moreover, an increase in the aging population prone to depression is expected to drive this segment over the forecast period.
Depressive disorder finds its primary treatment through medication with antidepressants that are prescribed by medical professionals according to each patient¢â‚¬â„¢s condition and requirements. However, there has been a rise in demand for non-prescription drugs due to high cost of prescription drugs and growing concerns regarding side effects associated with them. Thus Tricyclic Antidepressants (TCA) such as Imipramine are still widely used for treating Depressive Disorder despite availability of SSRIs which have fewer side effects than TCA class of antidepressants do.
Regional Analysis:
Europe dominated the global market in 2017. The presence of well-established healthcare facilities, availability of highly skilled psychiatrists and rapid uptake of novel drugs are some factors attributing to the region’s large share. Moreover, favorable reimbursement policies for antidepressants and an increase in awareness about mental disorders owing to various campaigns are also responsible for its largest share.
Asia Pacific is expected to witness a lucrative growth rate during the forecast period due to rising disposable income, improving healthcare infrastructure along with increasing prevalence of depressive disorder coupled with rise in consumer awareness about available treatment options & their efficacy. In addition, economic development & improvement in standard of living have led consumers towards a life fulled outwith home caregiving which further increases demand for medical assistance at outpatient settings as well as ambulatory surgical centers thus propelling regional growth over the forecast period.
Growth Factors:
- Increasing awareness about depressive disorder and its symptoms will help to drive the growth of the market.
- Rising incidence of depression due to various factors such as lifestyle changes, stress, and others will also fuel the growth of this market.
- Growing demand for antidepressants drugs owing to increasing prevalence of depressive disorders will propel the growth of this market in future years.
- Availability of various treatment options for depressive disorder is another key factor that would boost the growth prospects for this market in coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Depressive Disorder Market Research Report
By Type
Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist And Reuptake Inhibitors, Others
By Application
Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Homecare Settings, Long Term Care Centers
By Companies
Alkermes, Allergan, Bristol Myers Squibb, Eli Lilly, Glaxosmithkline, H. Lundbeck, Merck, Pfizer, Teva Pharmaceutical, Takeda Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
176
Number of Tables & Figures
124
Customization Available
Yes, the report can be customized as per your need.
Global Depressive Disorder Market Report Segments:
The global Depressive Disorder market is segmented on the basis of:
Types
Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist And Reuptake Inhibitors, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Homecare Settings, Long Term Care Centers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Alkermes
- Allergan
- Bristol Myers Squibb
- Eli Lilly
- Glaxosmithkline
- H. Lundbeck
- Merck
- Pfizer
- Teva Pharmaceutical
- Takeda Pharmaceutical
Highlights of The Depressive Disorder Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tricyclic Antidepressants
- Selective Serotonin Reuptake Inhibitors
- Serotonin-Norepinephrine Reuptake Inhibitors
- Monoamine Oxidase Inhibitors
- Serotonin Antagonist And Reuptake Inhibitors
- Others
- By Application:
- Hospitals
- Ambulatory Surgical Centers
- Diagnostic Centers
- Homecare Settings
- Long Term Care Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Depressive Disorder Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Depressive Disorder is a mental disorder that causes significant distress or impairment in daily life. People with depressive disorder may have problems with mood, energy, concentration, sleep, appetite and thoughts.
Some of the major players in the depressive disorder market are Alkermes, Allergan, Bristol Myers Squibb, Eli Lilly, Glaxosmithkline, H. Lundbeck, Merck, Pfizer, Teva Pharmaceutical, Takeda Pharmaceutical.
The depressive disorder market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Depressive Disorder Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Depressive Disorder Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Depressive Disorder Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Depressive Disorder Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Depressive Disorder Market Size & Forecast, 2020-2028
4.5.1 Depressive Disorder Market Size and Y-o-Y Growth
4.5.2 Depressive Disorder Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Tricyclic Antidepressants
5.2.2 Selective Serotonin Reuptake Inhibitors
5.2.3 Serotonin-Norepinephrine Reuptake Inhibitors
5.2.4 Monoamine Oxidase Inhibitors
5.2.5 Serotonin Antagonist And Reuptake Inhibitors
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Ambulatory Surgical Centers
6.2.3 Diagnostic Centers
6.2.4 Homecare Settings
6.2.5 Long Term Care Centers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Depressive Disorder Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Depressive Disorder Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Tricyclic Antidepressants
9.6.2 Selective Serotonin Reuptake Inhibitors
9.6.3 Serotonin-Norepinephrine Reuptake Inhibitors
9.6.4 Monoamine Oxidase Inhibitors
9.6.5 Serotonin Antagonist And Reuptake Inhibitors
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Ambulatory Surgical Centers
9.10.3 Diagnostic Centers
9.10.4 Homecare Settings
9.10.5 Long Term Care Centers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Tricyclic Antidepressants
10.6.2 Selective Serotonin Reuptake Inhibitors
10.6.3 Serotonin-Norepinephrine Reuptake Inhibitors
10.6.4 Monoamine Oxidase Inhibitors
10.6.5 Serotonin Antagonist And Reuptake Inhibitors
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Ambulatory Surgical Centers
10.10.3 Diagnostic Centers
10.10.4 Homecare Settings
10.10.5 Long Term Care Centers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Tricyclic Antidepressants
11.6.2 Selective Serotonin Reuptake Inhibitors
11.6.3 Serotonin-Norepinephrine Reuptake Inhibitors
11.6.4 Monoamine Oxidase Inhibitors
11.6.5 Serotonin Antagonist And Reuptake Inhibitors
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Ambulatory Surgical Centers
11.10.3 Diagnostic Centers
11.10.4 Homecare Settings
11.10.5 Long Term Care Centers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Tricyclic Antidepressants
12.6.2 Selective Serotonin Reuptake Inhibitors
12.6.3 Serotonin-Norepinephrine Reuptake Inhibitors
12.6.4 Monoamine Oxidase Inhibitors
12.6.5 Serotonin Antagonist And Reuptake Inhibitors
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Ambulatory Surgical Centers
12.10.3 Diagnostic Centers
12.10.4 Homecare Settings
12.10.5 Long Term Care Centers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Tricyclic Antidepressants
13.6.2 Selective Serotonin Reuptake Inhibitors
13.6.3 Serotonin-Norepinephrine Reuptake Inhibitors
13.6.4 Monoamine Oxidase Inhibitors
13.6.5 Serotonin Antagonist And Reuptake Inhibitors
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Ambulatory Surgical Centers
13.10.3 Diagnostic Centers
13.10.4 Homecare Settings
13.10.5 Long Term Care Centers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Depressive Disorder Market: Competitive Dashboard
14.2 Global Depressive Disorder Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Alkermes
14.3.2 Allergan
14.3.3 Bristol Myers Squibb
14.3.4 Eli Lilly
14.3.5 Glaxosmithkline
14.3.6 H. Lundbeck
14.3.7 Merck
14.3.8 Pfizer
14.3.9 Teva Pharmaceutical
14.3.10 Takeda Pharmaceutical
